STAT

•

頻道 • 2 個節目

商業

商業

每星期更新
新聞

新聞

每星期更新

25/10/2023

87: Why don’t the rules of war protect health care workers and facilities in Gaza?

In just two weeks, the brutality of the Israel-Hamas conflict has shocked the world. But one of its most heartbreaking aspects — the destruction of the already-struggling health care system in Gaza — is part of a decades-long pattern during war both in the region and around the world. Leonard Rubenstein is a distinguished professor of practice at the Johns Hopkins Bloomberg School of Public Health and author of “Perilous Medicine: The Struggle to Protect Health Care From the Violence of War.” On this episode of the First Opinion Podcast, we spoke about health care in war, the Geneva Conventions, and why it’s so difficult to hold those who break international law accountable.

25/10/2023

•

34 分鐘
30/10/2024

112: Abortion is just another part of medicine

This close to Nov. 5, we are being battered with promises that this race will determine the future of the country. But Christine Dehlendorf wants people to remember that as important as Election Day is, it won’t be the end of discussions about reproductive health. Dehlendorf is a family physician and professor of family and community medicine at the University of California, San Francisco and directs the Person-Centered Reproductive Health Program. Recently, she co-authored a First Opinion arguing that primary care providers and family physicians should have more training in providing abortion care.

30/10/2024

•

33 分鐘
02/02/2023

244: Pharma blockbusters, pandemic policy, & legal chicanery

STAT Washington correspondent Rachel Cohrs joins us to explain the looming end of Covid-19's status as a federal emergency and what that does and doesn't mean for public health. We also dig into the most interesting stories from a busy week of pharmaceutical earnings and discuss a legal setback for Johnson & Johnson.

02/02/2023

•

35 分鐘
30/06/2022

215: Medical privacy post-Roe, fixing clinical trials, & the next Covid vaccines

How do you stop a Covid surge? Why are clinical trials so white? And what are the limits of HIPAA? Our colleague Eric Boodman joins us to discuss whether an oft-cited federal law can shield reproductive health data from state law enforcement in the wake of Roe v. Wade being overturned. Then, STAT's Angus Chen calls in to relate the story of an ambitious study and the quest to finally make clinical trials more equitable. We also explain a momentous FDA meeting and the debate over just what the Covid-19 vaccines of the future should contain.

30/06/2022

•

34 分鐘
11/05/2023

258: Pharma vs. PBMs, Sarepta at the FDA, & a bold idea gone awry

We discuss a Senate hearing that put major pharma CEOs in the same room with the middlemen they love to blame for rising drug prices, with mixed results. We also explain what is a massive week for Sarepta Therapeutics, the FDA, and the future of gene therapies for rare diseases, plus the latest news in the life sciences.

11/05/2023

•

32 分鐘
30/03/2023

252: Biotech's monkey shortage, the broken generics market, & conference cancel culture

We explain how biotech is affected by a bizarre situation involving smuggled monkeys, international intrigue, and a criminal investigation. We also discuss what leads to generic drug shortages, whether every major pharmaceutical firm needs a weight-loss drug, and what it means when drug company cancels a conference appearance.

30/03/2023

•

36 分鐘
07/07/2022

216: VC malaise, FDA confusion, & yet another Alzheimer's debate

Is the era of the unicorn over? What's gotten into the FDA? And will a NASH drug ever work? Our colleague Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. We also discuss an FDA plot twist for a novel ALS treatment, a second shot for a once-promising liver drug, and the latest in the Covid-19 pandemic.

07/07/2022

•

29 分鐘
08/05/2025

352: A firebrand takes oversight of vaccines, gene therapies

Matt Herper joins Adam and Allison to examine Prasad's appointment and the band of outsiders now in charge of U.S. health agencies. He and Adam debate just how disruptive Prasad's tenure could be.

08/05/2025

•

26 分鐘
27/10/2022

232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms

Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.

27/10/2022

•

23 分鐘
18/05/2023

259: The FTC v. Amgen, Sarepta's future, & Galapagos' turnaround

Jared Holz, biotech strategist at Mizuho Securities, joins us to explain why federal regulators are suing to block Amgen's $28 billion merger with Horizon Therapeutics and what it means for the drug industry. We also discuss the latest on Sarepta Therapeutics and its gene therapy for Duchenne muscular dystrophy, a turnaround story in the making at the Belgian drug maker Galapagos, and the effort to secure approval for a maternal RSV vaccine.

18/05/2023

•

40 分鐘

Voices from the frontiers of health and medicine